Novavax (NVAX) investor relations material

Strategic transformation and partnerships

• Shifted from a COVID-focused company to a platform-driven business emphasizing partnerships and out-licensing of Matrix-M and nanoparticle technologies.

• Secured major deals with Sanofi in 2024 and Pfizer in January, with multiple additional partnership discussions and material transfer agreements underway.

• Pfizer agreement includes $30M upfront, up to $500M in milestones, and 20-year high mid-single digit royalties for two vaccine candidates.

• Partners are attracted by Matrix-M’s ability to enhance immune response, durability, and cost efficiency across various vaccine platforms.

• Vision includes a diversified portfolio of partners and assets, each generating milestone and royalty streams.

Research and development focus

• R&D supports data generation to demonstrate technology effectiveness, innovation in Matrix-M formulations, and development of new adjuvants targeting tough diseases and oncology.

• Pipeline includes three assets: C. diff, VZV, and RSV combination, with potential human trials as early as 2027.

• Matrix-M is being reengineered for oncology applications, aiming to elicit specific immune responses such as increased CD8-positive cells.

• Preclinical C. diff vaccine leverages multivalent design and mucosal immunity, with encouraging challenge study data and clinical entry targeted for 2027.

• R&D efforts create an innovation feedback loop, generating proof points that support both internal development and business development opportunities.

Key catalysts and future outlook

• Anticipated catalysts include new partnership announcements, progress on existing deals (notably with Sanofi and Pfizer), and R&D data releases.

• Sanofi’s full-cycle launch of NUVAXOVID under BLA and advancement of combination vaccine programs are expected to be significant milestones.

• Ongoing cost reduction and lean operations, with core spend targeted at $200M or below starting in 2026.

• Patent protection for Matrix-M extends into the 2040s, with additional layers of IP and manufacturing know-how providing competitive advantage.

• Strong balance sheet and cash runway projected to last into 2028, with a path to non-GAAP profitability as early as 2028.